MGMT methylation: A marker of response to temozolomide in low‐grade gliomas
- 27 December 2006
- journal article
- clinical trial
- Published by Wiley in Annals of Neurology
- Vol. 60 (6), 740-743
- https://doi.org/10.1002/ana.21044
Abstract
The methylation status of the O6‐methylguanine‐methyltransferase promoter (MGMTP) was evaluated in 68 low‐grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression‐free survival as compared with unmethylated MGMTP tumors (p < 0.0001). Assessment of MGMTP status could help identifying low‐grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies. Ann Neurol 2006;60:740–743Keywords
This publication has 16 references indexed in Scilit:
- Progressive low‐grade oligodendrogliomasCancer, 2006
- Chromosome 1p loss: A favorable prognostic factor in low‐grade gliomasAnnals of Neurology, 2005
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumorsInternational Journal of Cancer, 2004
- Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p DeletionsJournal of Clinical Oncology, 2004
- CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary GliomasClinical Cancer Research, 2004
- Brain tumours: classification and genesJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with TemozolomideClinical Cancer Research, 2004
- Primary brain tumours in adultsThe Lancet, 2003
- Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomasActa Neuropathologica, 2001